This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.
Cancer Gene Therapy, edited by R. E. Sobol and K. J. Scanlon, quarterly, $175 (institutions), $80 (individuals), Norwalk, Conn, Appleton & Lange, March 1994-.
Despite the phenomenal growth in research and clinical trials of gene therapy, until recently the only journal devoted exclusively to the topic was Human Gene Therapy (New York, NY: Mary Ann Liebert; 1990- ). Last year, two new journals, Gene Therapy and Cancer Gene Therapy, were founded to help carry the rising publication load.
Human Gene Therapy continues to be the dominant journal in the field in terms of number and quality of articles. Yet, the two new entries seem well positioned to compete effectively, each taking a slightly different approach. Both of the new journals are peer-reviewed publications that present articles for clinicians as well as basic researchers. Both new journals contain primarily research articles along with some reports of current clinical trials. They present their
Albright ED, Bouck N. Gene Therapy. JAMA. 1995;274(17):1404. doi:10.1001/jama.1995.03530170084040